002412.SZ
Hunan Hansen Pharmaceutical Co. Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 11.21
+10.01%Year over year
Reported trailing growth
- Revenue
- +1.3%
- EBITDA
- —
- EBIT
- +27.5%
- EPS
- +30.0%
- Free cash flow
- +20.0%
- Operating cash flow
- +16.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +4.3%
- EBITDA
- +5.2%
- EBIT
- +8.2%
- Net income
- +5.7%
- EPS
- +5.7%
- Free cash flow
- +21.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026